Pfizer has named Paul Burke as the CTO of its oligonucleotide therapeutics unit.
Burke joins Pfizer from Merck, where he served as executive director of RNA therapeutics. Before that, he was an executive director at Amgen. He holds a PhD in chemistry from the Massachusetts Institute of Technology.
He replaces C. Satishchandran, who left Pfizer to become director of the Center for Biopharmaceutical Research and Production at North Dakota State University, Fargo.